Diabetic retinopathy, oxidative stress, and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons.
AntagomiR
Antioxidants
Coumarin
Diabetes mellitus
Diabetic retinopathy
Novel therapies
Oxidative stress
Resveratrol
Sirtuin
Journal
Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551
Informations de publication
Date de publication:
Historique:
received:
01
05
2020
revised:
03
04
2021
accepted:
05
04
2021
pubmed:
18
4
2021
medline:
31
3
2022
entrez:
17
4
2021
Statut:
ppublish
Résumé
Diabetic retinopathy (DR) is one of the leading causes of blindness in the world. DR represents the most common microvascular complication of diabetes, and its incidence is constantly rising. The complex interactions between inflammation, oxidative stress, and the production of free oxygen radicals caused by prolonged exposure to hyperglycemia determine the development of DR. Sirtuins (SIRTs) are a recently discovered class of 7 histone deacetylases involved in cellular senescence, regulation of cell cycle, metabolic pathways, and DNA repair. SIRTs participate in the progress of several pathologies such as cancer, neurodegeneration, and metabolic diseases. In DR sirtuins 1,3,5, and 6 play an important role as they regulate the activation of the inflammatory response, insulin sensibility, and both glycolysis and gluconeogenesis. A wide spectrum of direct and indirect activators of SIRTs pathways (e.g., antagomiR, resveratrol, or glycyrrhizin) is currently being developed to treat the inflammatory cascade occurring in DR. We focus on the main metabolic and inflammatory pathways involving SIRTs and DR, as well as recent evidence on SIRTs activators that may be employed as novel therapeutic approaches to DR.
Identifiants
pubmed: 33864872
pii: S0039-6257(21)00101-6
doi: 10.1016/j.survophthal.2021.04.003
pii:
doi:
Substances chimiques
Sirtuins
EC 3.5.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
168-183Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest None.